
The Cannabinoids Biopharma Company
RS Biotherapeutic’s mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life-changing medicines. RS BioTherapeutic’s first investigational compound (RSBT-001) is a patent-pending, semi-synthetic cannabidiolic acid complex in development to replace corticosteroids in addressing exacerbation and preventing progression of both acute and chronic pulmonary inflammation related to respiratory diseases including COPD, SARS-COV-2, Cystic Fibrosis, Asthma, Bronchitis, and Acute Respiratory Distress Syndrome. RS BioTherapeutics is targeting an IND filing for RSBT-001 in early 2025.
Leadership Team
Our leadership team is comprised of industry leaders and specialists who are committed to the advancement of our vision and mission.
Contact Us